A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

(2016) Laurie H Sehn et al.   LANCET ONCOLOGY

Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies

(2015) T. R. W. Tipton et al.   BLOOD

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

(2015) A. H. Rook et al.   BLOOD

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

(2015) David J. DiLillo et al.   CELL

Immuno-regulatory antibodies for the treatment of cancer

(2015) Jamie Honeychurch et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination

(2015) Kavin Fatehchand et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The TLR7 agonist induces tumor regression both by promoting CD4+T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells

(2015) Chenchen Wang et al.   Oncotarget

Update on obinutuzumab in the treatment of B-cell malignancies

(2014) Tim Illidge et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Modes of action of TLR7 agonists in cancer therapy

(2014) Sebastian Kobold et al.   Immunotherapy

Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice

(2014) C Deligne et al.   LEUKEMIA

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

(2013) J. Golay et al.   BLOOD

The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab

(2013) Eleanor J. Cheadle et al.   BRITISH JOURNAL OF HAEMATOLOGY

GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present

(2013) Delila J. Kern et al.   LEUKEMIA & LYMPHOMA

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

(2013) Frank Herting et al.   LEUKEMIA & LYMPHOMA

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

(2013) S. Herter et al.   MOLECULAR CANCER THERAPEUTICS

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma

(2012) S. J. Dovedi et al.   BLOOD

Combination of Cyclophosphamide, Rituximab, and Intratumoral CpG Oligodeoxynucleotide Successfully Eradicates Established B cell Lymphoma

(2012) David J. Betting et al.   JOURNAL OF IMMUNOTHERAPY

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab

(2011) B. E. Wahlin et al.   CLINICAL CANCER RESEARCH

VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC

(2011) H. Lu et al.   CLINICAL CANCER RESEARCH

Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice

(2011) Mayuka Horikawa et al.   JOURNAL OF CLINICAL INVESTIGATION

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

(2011) S. Dalle et al.   MOLECULAR CANCER THERAPEUTICS

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

(2010) R. Abes et al.   BLOOD

Reciprocal Regulation of Activating and Inhibitory Fc  Receptors by TLR7/8 Activation: Implications for Tumor Immunotherapy

(2010) J. P. Butchar et al.   CLINICAL CANCER RESEARCH

Indirect Inhibition of Toll-like Receptor and Type I Interferon Responses by ITAM-Coupled Receptors and Integrins

(2010) Lu Wang et al.   IMMUNITY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

(2009) S. P. Hilchey et al.   BLOOD

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

(2009) Jonathan W. Friedberg et al.   BRITISH JOURNAL OF HAEMATOLOGY

Intratumoral But Not Systemic Delivery of CpG Oligodeoxynucleotide Augments the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Against B Cell Lymphoma

(2009) David J. Betting et al.   JOURNAL OF IMMUNOTHERAPY

Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)

(2008) María Moreno et al.   CANCER LETTERS

TLR7 and TLR8 as targets in cancer therapy

(2008) M P Schön et al.   ONCOGENE

NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma

(2007) Esther Moga et al.   EXPERIMENTAL HEMATOLOGY